ImmunoGen Needs Another Phase III For Its ADC In Ovarian Cancer
Executive Summary
The biotech’s hopes for an accelerated approval on subgroup data were dashed by the US FDA, but it will work with the agency to design a Phase III focused on highly FRα-positive patients.
You may also be interested in...
Pipeline Watch: Phase III Readouts For Rapastinel, VX-445 And Mirvetuximab Soravtansine
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Ovarian Cancer Pipeline Review: Sponsors Plan Frontline Punch, Smart Combinations
Combination studies of drugs for ovarian cancer have heavy focus on PARP, PD-1/L1 and VEGF mechanisms.
Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications
Accelerated approval in epithelioid sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports